ストックスクリーナーアプリを入手
1.75
3.55%
0.06
アフターアワーズ：
1.78
0.03
+1.71%
前日終値:
$1.69
開ける：
$1.73
24時間の取引高:
166.63K
Relative Volume:
2.08
時価総額：
$2.50M
収益：
-
当期純損益:
$-7.98M
株価収益率:
-0.1996
EPS:
-8.7693
ネットキャッシュフロー:
$-6.49M
1週間 パフォーマンス:
+2.34%
1か月 パフォーマンス:
-4.37%
6か月 パフォーマンス:
-82.57%
1年 パフォーマンス:
-88.94%
1日の値動き範囲:
$1.73
$1.89
1週間の範囲:
$1.67
$1.89
52週間の値動き範囲:
$1.54
$30.25
Adial Pharmaceuticals Inc Stock (ADIL) Company Profile
名前
Adial Pharmaceuticals Inc
セクター
電話
434-422-9800
住所
1180 SEMINOLE TRAIL, CHARLOTTESVILLE, VA
Compare ADIL vs VRTX, REGN, ARGX, ALNY, INSM
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ADIL
Adial Pharmaceuticals Inc
|
1.75 | 2.41M | 0 | -7.98M | -6.49M | -8.7693 |
VRTX
Vertex Pharmaceuticals Inc
|
434.30 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
763.04 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
748.25 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
330.34 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.81 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Adial Pharmaceuticals Inc Stock (ADIL) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-11-14 | 開始されました | Rodman & Renshaw | Buy |
| 2018-10-30 | 開始されました | Maxim Group | Buy |
| 2018-10-11 | 開始されました | Dawson James | Buy |
Adial Pharmaceuticals Inc (ADIL) 最新ニュース
Investor Mood: Will Adial Pharmaceuticals Inc benefit from government policy2026 Selloffs & AI Enhanced Trading Signals - baoquankhu1.vn
Hedge Fund Bets: Whats the MACD signal for Adial Pharmaceuticals Inc2026 Dividend Review & Free Low Drawdown Momentum Trade Ideas - baoquankhu1.vn
Market Moves: Whats Adial Pharmaceuticals Incs historical returnDollar Strength & Daily Stock Trend Reports - baoquankhu1.vn
Aug Closing: Does Adial Pharmaceuticals Inc offer margin of safetyStock Surge & Fast Entry Momentum Trade Alerts - baoquankhu1.vn
Valuation Update: Will Adial Pharmaceuticals Inc benefit from geopolitical trends2026 Review & Weekly Chart Analysis and Trade Guides - baoquankhu1.vn
Adial Pharmaceuticals Lead Drug Fits New Policy Mood As Bipartisan Bill Signals Broader Lens On Alcohol Use Disorder - Sahm
Adial Pharmaceuticals Commends Introduction of H.R. 7091 to Expand Access to Alcohol Use Disorder Treatments for Veterans - Quiver Quantitative
Adial Pharmaceuticals Commends Congress on Introduction of - globenewswire.com
Nearly 40% of veterans face AUD; new bill backs more therapy research - Stock Titan
Smart Money: Does Adial Pharmaceuticals Inc have a competitive edge2026 Trade Ideas & Daily Stock Trend Reports - baoquankhu1.vn
Nasdaq Moves: Whats the beta of Adial Pharmaceuticals Inc stock2026 Analyst Calls & Real-Time Volume Analysis - baoquankhu1.vn
Revenue per share of Adial Pharmaceuticals, Inc – NASDAQ:ADIL - TradingView
Tech Rally: Whats the fair value of Adial Pharmaceuticals Inc stockPortfolio Risk Summary & Expert Approved Momentum Trade Ideas - baoquankhu1.vn
Is Adial Pharmaceuticals Inc. stock a smart buy before Fed meetingPortfolio Return Report & High Conviction Investment Ideas - Naître et grandir
Key facts: Adial Pharmaceuticals reports $7.98M annual loss; 2025 results show regulatory progress - TradingView
Adial Pharmaceuticals (ADIL) Enhances Financial Position and Cli - GuruFocus
Adial Pharmaceuticals Reports 2025 Fiscal Year Financial Results and Provides Business Update - TradingView
Adial Pharmaceuticals (NASDAQ: ADIL) outlines AD04 advances, Europe deal and Nasdaq win - Stock Titan
Adial Pharmaceuticals 10-K: $(7.98M) Net Loss, $(11.93) EPS; Cash into H2 2026 - TradingView
Adial Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
ADIL SEC FilingsAdial Pharmaceuticals Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Adial Pharmaceuticals signs framework deal with Molteni for Europe By Investing.com - Investing.com Canada
Adial Pharmaceuticals (ADIL) Plans European Expansion for AD04 w - GuruFocus
Adial Pharmaceuticals signs exclusive AD04 collaboration framework with Molteni Farmaceutici for Europe - marketscreener.com
Adial Pharmaceuticals signs framework deal with Molteni for Europe - Investing.com
Adial Pharmaceuticals Secures European Partnership for AD04 Commercialization - TipRanks
Adial Pharmaceuticals enters exclusive AD04 Europe framework with Molteni; potential $60M in royalties & milestones - TradingView
Adial (NASDAQ: ADIL) outlines AD04 Europe deal framework with Molteni - Stock Titan
Adial Pharmaceuticals, Inc. Enters into A Collaboration Framework Agreement with Molteni Farmaceutici - marketscreener.com
EXCLUSIVE: Adial Pharma Eyes Europe Deal For Lead Drug For Alcohol Use Disrder Worth Up To $60 Million - Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Adial Pharmaceuticals (ADIL) to Release Quarterly Earnings on Tuesday - Defense World
Adial Pharmaceuticals Highlights FDA Policy Direction That May Reduce Pivotal Trial Burden from Two Studies to One - ADVFN Ltd
Adial Pharmaceuticals, IncWarrant (NQ: ADILW - The Chronicle-Journal
Adial Pharmaceuticals Secures Exchange Listing Amid Regulatory Tailwinds - AD HOC NEWS
Short Interest in Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Decreases By 87.7% - Defense World
ADIL Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Adial Pharmaceuticals Regains Nasdaq Compliance, Advances AD04 Program - The Globe and Mail
ARMISTICE CAPITAL, LLC Acquires Shares in Adial Pharmaceuticals Inc - GuruFocus
Key facts: Adial Pharmaceuticals meets Nasdaq bid requirement; advances AD04 to Phase 3 trial - TradingView
Adial Pharmaceuticals Regains Full Compliance with Nasdaq Listing Requirement - Bitget
Adial Pharmaceuticals regains full compliance with Nasdaq listing requirement - marketscreener.com
Adial Regains Nasdaq Compliance as AD04 Advances, Engages in Partnering Talks - TradingView
Adial Pharmaceuticals Regains Full Compliance With Nasdaq Listing Requirement - TradingView
Adial Pharmaceuticals (ADIL) regains Nasdaq compliance, highlights AD04 Phase 3 path - Stock Titan
Adial Pharmaceuticals eyes single pivotal trial path for AD04 - Investing.com India
Adial Pharmaceuticals eyes single pivotal trial path for AD04 By Investing.com - Investing.com Australia
Adial Pharmaceuticals stock rises on FDA policy shift By Investing.com - Investing.com South Africa
Adial Pharmaceuticals stock rises on FDA policy shift - Investing.com
Adial Pharmaceuticals (ADIL) Sees Potential in FDA's New Approva - GuruFocus
Adial Pharmaceuticals Inc (ADIL) 財務データ
収益
当期純利益
現金流量
EPS
0.87%
0.11%
大文字化:
|
ボリューム (24 時間):